间变性大细胞淋巴瘤：世界卫生组织分类的变化及靶向治疗前景
Anaplastic large cell lymphoma: changes in the World Health Organization classification and perspectives for targeted therapy.
作者信息
Falini Brunangelo, Martelli Maria Paola
出版信息
Haematologica. 2009 Jul;94(7):897-900. doi: 10.3324/haematol.2009.008250.
Abstract
The accompanying perspective by Drs. Falini and Martelli provides a clear description of the current WHO classification with a focus on the distinction between ALK-positive anaplastic large cell lymphoma ALCL and ALK-negative disease. Additionally, they provide a rationale for potential new targets for therapy including flavopiridol. See related paper on page 944.
摘要
法利尼博士和马尔泰利博士随附的观点明确描述了世界卫生组织的现行分类，重点在于ALK阳性间变性大细胞淋巴瘤（ALCL）与ALK阴性疾病之间的区别。此外，他们还阐述了包括黄酮哌啶醇在内的潜在新治疗靶点的理论依据。见第944页的相关论文。
相似文献
1
Anaplastic large cell lymphoma: changes in the World Health Organization classification and perspectives for targeted therapy.间变性大细胞淋巴瘤：世界卫生组织分类的变化及靶向治疗前景
Haematologica. 2009 Jul;94(7):897-900. doi: 10.3324/haematol.2009.008250.
2
Cytokeratin positivity in anaplastic large cell lymphoma: a potential diagnostic pitfall in misdiagnosis of metastatic carcinoma.间变性大细胞淋巴瘤中的细胞角蛋白阳性：转移性癌误诊中的一个潜在诊断陷阱。
Int J Clin Exp Pathol. 2013;6(4):798-801. Epub 2013 Mar 15.
3
Primary anaplastic large cell lymphoma of the kidney.原发性肾间变性大细胞淋巴瘤
Leuk Lymphoma. 2003 Feb;44(2):353-5. doi: 10.1080/1042819021000030027.
4
Expression of p63 in anaplastic large cell lymphoma but not in classical Hodgkin's lymphoma.p63在间变性大细胞淋巴瘤中表达，但在经典型霍奇金淋巴瘤中不表达。
Hum Pathol. 2008 Oct;39(10):1505-10. doi: 10.1016/j.humpath.2008.02.016. Epub 2008 Jul 11.
5
B-cell anaplastic large cell lymphoma--the forgotten entity.B细胞间变性大细胞淋巴瘤——被遗忘的实体。
Am J Surg Pathol. 2000 Jan;24(1):159-60. doi: 10.1097/00000478-200001000-00033.
6
Anaplastic large cell lymphoma: pathological, molecular and clinical features.间变性大细胞淋巴瘤：病理、分子及临床特征
Br J Haematol. 2001 Sep;114(4):741-60. doi: 10.1046/j.1365-2141.2001.02896.x.
7
Anaplastic lymphoma kinase-negative anaplastic large cell lymphoma with colon involvement.伴有结肠受累的间变性淋巴瘤激酶阴性间变性大细胞淋巴瘤
Can J Gastroenterol Hepatol. 2015 Oct;29(7):345-6. doi: 10.1155/2015/897860. Epub 2015 Aug 31.
8
Anaplastic large cell lymphoma presenting as an endobronchial polypoid mass.表现为支气管内息肉样肿块的间变性大细胞淋巴瘤。
Leuk Lymphoma. 2012 Oct;53(10):2078-9. doi: 10.3109/10428194.2012.670234. Epub 2012 Mar 16.
9
Anaplastic lymphoma kinase negative sarcomatoid variant of anaplastic large-cell lymphoma presenting as a malignant fibrous histiocytoma.间变性大细胞淋巴瘤的间变性淋巴瘤激酶阴性肉瘤样变体，表现为恶性纤维组织细胞瘤。
Virchows Arch. 2003 Jun;442(6):611-3. doi: 10.1007/s00428-003-0789-z. Epub 2003 Apr 5.
10
[ALK+ diffuse large B-cell lymphoma].[ALK 阳性弥漫性大 B 细胞淋巴瘤]
Ann Pathol. 2012 Oct;32(5):351-5. doi: 10.1016/j.annpat.2012.08.001. Epub 2012 Oct 9.
引用本文的文献
1
Case report: diagnostic challenges of primary central nervous system anaplastic large cell lymphoma, ALK-positive.病例报告：ALK阳性的原发性中枢神经系统间变性大细胞淋巴瘤的诊断挑战
Childs Nerv Syst. 2025 Jul 23;41(1):241. doi: 10.1007/s00381-025-06904-3.
2
Role of ALK Inhibitors in Anaplastic Large Cell Lymphoma-Experience from an Indian Center.ALK抑制剂在间变性大细胞淋巴瘤中的作用——来自印度一家中心的经验。
South Asian J Cancer. 2023 Aug 12;13(2):121-125. doi: 10.1055/s-0042-1758353. eCollection 2024 Apr.
3
Podcast on Emerging Treatment Options for Pediatric Patients with ALK-Positive Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumors.关于ALK阳性间变性大细胞淋巴瘤和炎性肌纤维母细胞瘤儿科患者新兴治疗选择的播客。
Oncol Ther. 2024 Jun;12(2):247-255. doi: 10.1007/s40487-024-00275-6. Epub 2024 Apr 27.
4
Analysis and therapeutic targeting of the IL-1R pathway in anaplastic large cell lymphoma.间变大细胞淋巴瘤中白介素-1 受体通路的分析与治疗靶点。
Blood. 2023 Oct 12;142(15):1297-1311. doi: 10.1182/blood.2022019166.
5
Primary anaplastic large cell lymphomas of the pancreas.胰腺原发性间变性大细胞淋巴瘤
Proc (Bayl Univ Med Cent). 2022 Jun 7;35(5):675-677. doi: 10.1080/08998280.2022.2082228. eCollection 2022.
6
A novel model of alternative NF-κB pathway activation in anaplastic large cell lymphoma.在间变大细胞淋巴瘤中，一种新的非经典 NF-κB 通路激活模型。
Leukemia. 2021 Jul;35(7):1976-1989. doi: 10.1038/s41375-020-01088-y. Epub 2020 Nov 12.
7
NPM-ALK Is a Key Regulator of the Oncoprotein FOXM1 in ALK-Positive Anaplastic Large Cell Lymphoma.NPM-ALK是ALK阳性间变性大细胞淋巴瘤中癌蛋白FOXM1的关键调节因子。
Cancers (Basel). 2019 Aug 6;11(8):1119. doi: 10.3390/cancers11081119.
8
Current Approaches Including Novel Nano/Microtechniques to Reduce Silicone Implant-Induced Contracture with Adverse Immune Responses.当前方法包括新型纳米/微技术，以减少因免疫反应不良而导致的硅酮植入物引起的挛缩。
Int J Mol Sci. 2018 Apr 12;19(4):1171. doi: 10.3390/ijms19041171.
9
The Role of Activator Protein-1 (AP-1) Family Members in CD30-Positive Lymphomas.激活蛋白-1（AP-1）家族成员在CD30阳性淋巴瘤中的作用
Cancers (Basel). 2018 Mar 28;10(4):93. doi: 10.3390/cancers10040093.
10
ALK+ Anaplastic Large Cell Lymphoma With Bladder Involvement Presenting as Fever of Unknown Origin: A Case Report and Literature Review.伴有膀胱受累的ALK+间变性大细胞淋巴瘤表现为不明原因发热：病例报告及文献复习
World J Oncol. 2013 Apr;4(2):95-101. doi: 10.4021/wjon644w. Epub 2013 May 6.
本文引用的文献
1
The effect of the cyclin-dependent kinase inhibitor flavopiridol on anaplastic large cell lymphoma cells and relationship with NPM-ALK kinase expression and activity.细胞周期蛋白依赖性激酶抑制剂氟吡汀对间变性大细胞淋巴瘤细胞的作用及其与NPM-ALK激酶表达和活性的关系。
Haematologica. 2009 Jul;94(7):944-55. doi: 10.3324/haematol.2008.004861. Epub 2009 Jun 16.
2
Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas.间变性淋巴瘤激酶免疫反应性与非小细胞肺癌中的ALK基因重排及转录上调相关。
Hum Pathol. 2009 Aug;40(8):1152-8. doi: 10.1016/j.humpath.2009.01.012. Epub 2009 Apr 22.
3
EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues.非小细胞肺癌和非肿瘤性肺组织中的EML4-ALK重排
Am J Pathol. 2009 Feb;174(2):661-70. doi: 10.2353/ajpath.2009.080755. Epub 2009 Jan 15.
4
Proteome-wide identification of novel binding partners to the oncogenic fusion gene protein, NPM-ALK, using tandem affinity purification and mass spectrometry.利用串联亲和纯化和质谱技术对致癌融合基因蛋白NPM-ALK的新型结合伴侣进行全蛋白质组鉴定。
Am J Pathol. 2009 Feb;174(2):361-70. doi: 10.2353/ajpath.2009.080521. Epub 2009 Jan 8.
5
The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL.5-氨基咪唑-4-甲酰胺核糖核苷酸甲酰基转移酶/肌苷酸环化水解酶的酶活性被NPM-ALK增强：间变性淋巴瘤激酶介导的发病机制及间变性大细胞淋巴瘤治疗的新见解
Blood. 2009 Mar 19;113(12):2776-90. doi: 10.1182/blood-2008-06-161018. Epub 2008 Oct 9.
6
Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosis.雷帕霉素通过抑制mTOR信号通路、增强G1期细胞周期阻滞和凋亡，逆转NPM-ALK诱导的淋巴瘤细胞糖皮质激素耐药性。
Leukemia. 2008 Nov;22(11):2091-6. doi: 10.1038/leu.2008.204. Epub 2008 Aug 7.
7
Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.间变性淋巴瘤激酶的基因组改变可能使肿瘤对间变性淋巴瘤激酶抑制剂敏感。
Cancer Res. 2008 May 1;68(9):3389-95. doi: 10.1158/0008-5472.CAN-07-6186.
8
ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project.ALK-间变性大细胞淋巴瘤在临床和免疫表型上与ALK+间变性大细胞淋巴瘤及外周T细胞淋巴瘤（未另行指定）均不同：来自国际外周T细胞淋巴瘤项目的报告
Blood. 2008 Jun 15;111(12):5496-504. doi: 10.1182/blood-2008-01-134270. Epub 2008 Apr 2.
9
The anaplastic lymphoma kinase in the pathogenesis of cancer.间变性淋巴瘤激酶在癌症发病机制中的作用
Nat Rev Cancer. 2008 Jan;8(1):11-23. doi: 10.1038/nrc2291.
10
A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies.一项针对难治性或复发性CD30+血液系统恶性肿瘤患者的SGN-30免疫疗法1期多剂量研究。
Blood. 2008 Feb 15;111(4):1848-54. doi: 10.1182/blood-2007-07-099317. Epub 2007 Dec 13.
Zotero 插件